Navigation path

Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Hiprabovis IBR Marker Live   
Auth. number : EU/2/10/114
INN : Live gE- tk- double-gene deleted Bovine Herpes Virus type 1 (BoHV-1), strain CEDDEL
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI02 - Immunologicals for bovidae
Pharmacological subgroup: QI02A - Cattle
Chemical subgroup: QI02AD - Live viral vaccines
Chemical substance: QI02AD01 - Bovine rhinotracheitis virus (IBR)
(See WHO ATCvet Index)
Indication: For the active immunisation of cattle from 3 months of age against Bovine Herpes Virus type 1 (BoHV-1) to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
Marketing Authorisation Holder: Laboratorios Hipra, S.A.
Avda. La Selva, 135, E-17170- Amer (Girona), España

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/02/2011 Centralised - Authorisation EMEA/V/C/158 (2011)579 of 27/01/2011
11/01/2012 Centralised - Variation EMEA/V/C/158/II/1 (2012)90 of 09/01/2012
19/07/2013 Centralised - Variation EMEA/V/C/15/IB/2
Updated with Decision(2014)4507 of 27/06/2014
01/07/2014 Centralised - Yearly update (2014)4507 of 27/06/2014